IgM anti-hepatitis C virus core antibodies as marker of recurrent hepatitis C after liver transplantation.
The differential diagnosis of recurrent hepatitis C following orthotopic liver transplantation (OLT) may be difficult. We evaluated the diagnostic significance of IgM anti-hepatitis C virus (anti-HCV) core antibodies in 27 patients undergoing OLT because of HCV-associated cirrhosis. Serial serum samples collected before and after OLT were tested for the presence of IgM anti-HCV core antibodies. Results were compared with the histological evidence of liver damage, the presence, level, and genotype of serum HCV RNA and the degree of immunosuppression. All patients underwent recurrent HCV infection. Recurrent hepatitis was diagnosed histologically in 21 patients an average of 48 weeks after OLT (range 2-209 weeks): 18 had persistence or (re-)appearance of the IgM anti-HCV core after OLT, one lost the IgM anti-HCV core after OLT, and two never secreted IgM anti-HCV core either before or after OLT. The remaining six patients did not develop recurrent hepatitis after a follow-up of 44-241 weeks from OLT; in these patients, IgM anti-HCV core either disappeared (1 case) or decreased (1 case) after OLT or were persistently negative throughout the study (4 cases). Thus, 18/21 patients with recurrent hepatitis, but only one of six without recurrent hepatitis, secreted IgM anti-HCV core after OLT (P < 0.05). The IgM anti-HCV core levels were not correlated with the level or genotype of serum HCV RNA or the degree of immunosuppression. In conclusion, secretion of IgM anti-HCV core antibodies after OLT seems associated with recurrence of HCV-associated liver disease and may have diagnostic significance.
Negro
F
F
Division of Gastroenterology and Hepatology, University Hospital, Geneva, Switzerland. francesco.negro@hcuge.ch
Giostra
E
E
Rubbia-Brandt
L
L
Mentha
G
G
Colucci
G
G
Morel
P
P
Quadri
R
R
Perrin
L
L
Hadengue
A
A
D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D015415:Biomarkers; D005260:Female; D005838:Genotype; D006084:Graft Rejection / Q000628:therapy; D016174:Hepacivirus / Q000145:classification / Q000235:genetics; D006526:Hepatitis C / Q000175:diagnosis*; D018937:Hepatitis C Antibodies / Q000097:blood*; D006801:Humans; D007075:Immunoglobulin M / Q000097:blood*; D007165:Immunosuppression Therapy; D008103:Liver Cirrhosis / Q000601:surgery / Q000821:virology; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000175:diagnosis*; D012367:RNA, Viral / Q000097:blood; D012008:Recurrence; D014758:Viral Core Proteins / Q000276:immunology*
D015415:Biomarkers; D018937:Hepatitis C Antibodies; D007075:Immunoglobulin M; D012367:RNA, Viral; D014758:Viral Core Proteins; C069130:nucleocapsid protein, Hepatitis C virus; D000410:Alanine Transaminase